Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) closed at $401.0 up 2.55% from its previous closing price of $391.02. In other words, the price has increased by $2.55 from its previous closing price. On the day, 1.86 million shares were traded. VRTX stock price reached its highest trading level at $401.555 during the session, while it also had its lowest trading level at $390.79.
Ratios:
For a deeper understanding of Vertex Pharmaceuticals, Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.08 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 29.38. For the most recent quarter (mrq), Quick Ratio is recorded 2.16 and its Current Ratio is at 2.52. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 27 ’25 when Bhatia Sangeeta N. sold 266 shares for $386.69 per share. The transaction valued at 102,860 led to the insider holds 4,565 shares of the business.
Bhatia Sangeeta N. bought 266 shares of VRTX for $102,860 on Aug 27 ’25. On Aug 06 ’25, another insider, Kewalramani Reshma, who serves as the CEO & President of the company, bought 10,000 shares for $389.58 each. As a result, the insider paid 3,895,768 and bolstered with 115,968 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRTX now has a Market Capitalization of 102812794880 and an Enterprise Value of 97957249024. As of this moment, Vertex’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.66, and their Forward P/E ratio for the next fiscal year is 19.44. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.02 while its Price-to-Book (P/B) ratio in mrq is 5.98. Its current Enterprise Value per Revenue stands at 8.579 whereas that against EBITDA is 20.402.
Stock Price History:
The Beta on a monthly basis for VRTX is 0.44, which has changed by -0.16208702 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, VRTX has reached a high of $519.88, while it has fallen to a 52-week low of $362.50. The 50-Day Moving Average of the stock is -7.26%, while the 200-Day Moving Average is calculated to be -11.68%.
Shares Statistics:
For the past three months, VRTX has traded an average of 1.65M shares per day and 1631240 over the past ten days. A total of 256.29M shares are outstanding, with a floating share count of 255.58M. Insiders hold about 0.32% of the company’s shares, while institutions hold 96.28% stake in the company. Shares short for VRTX as of 1755216000 were 3700693 with a Short Ratio of 2.24, compared to 1752537600 on 4188160. Therefore, it implies a Short% of Shares Outstanding of 3700693 and a Short% of Float of 1.63.
Earnings Estimates
The stock of Vertex Pharmaceuticals, Inc (VRTX) is currently in the spotlight, with 21.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $4.95, with high estimates of $5.29 and low estimates of $4.58.
Analysts are recommending an EPS of between $18.83 and $16.61 for the fiscal current year, implying an average EPS of $18.06. EPS for the following year is $20.3, with 23.0 analysts recommending between $23.6 and $18.31.
Revenue Estimates
A total of 26 analysts believe the company’s revenue will be $3.06B this quarter.It ranges from a high estimate of $3.14B to a low estimate of $2.94B. As of the current estimate, Vertex Pharmaceuticals, Inc’s year-ago sales were $2.77BFor the next quarter, 26 analysts are estimating revenue of $3.21B. There is a high estimate of $3.29B for the next quarter, whereas the lowest estimate is $3.1B.
A total of 29 analysts have provided revenue estimates for VRTX’s current fiscal year. The highest revenue estimate was $12.13B, while the lowest revenue estimate was $11.89B, resulting in an average revenue estimate of $12B. In the same quarter a year ago, actual revenue was $11.02BBased on 27 analysts’ estimates, the company’s revenue will be $13.18B in the next fiscal year. The high estimate is $14.36B and the low estimate is $11.94B.
